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Norovirus
Julie Schlegel, MSP
Foodborne Epidemiologist
DHEC, Division of Acute Disease Epidemiology
Libby Greene, MSN, APRN, BC
Director, Surveillance Section/Nurse Consultant
DHEC, Division of Acute Disease Epidemiology
Noroviruses are RNA viruses that cause acute gastroen-
teritis in humans. The name “Norovirus” was recently ap-
proved as the official genus name for the group of viruses
previously described as “Norwalk-like viruses”.
Noroviruses are transmitted primarily through the fecal-
oral route, either by direct person-to-person contact or by
contaminated surface, food, or water. Noroviruses can also
spread by droplets from vomitus.  In addition, transmis-
sion often occurs through hand transfer of the virus to the
oral mucosa via contact with materials, fomites, and envi-
ronmental surfaces that have been contaminated with ei-
ther feces or vomitus. Contaminated surfaces handled by
multiple persons such as doorknobs, sink hardware, or
other shared items are the likely source of many infec-
tions.   Noroviruses are highly contagious, with as few as
10 virus particles probably sufficient to cause infection.
These viruses are relatively stable in the environment and
can survive freezing and heating to 60 degrees Celsius
(140 degrees Fahrenheit).
The average incubation period for norovirus-associated
gastroenteritis is 12 to 48 hours, with a median of about
33 hours. Symptoms usually last 24 to 60 hours and in-
clude acute-onset of vomiting, watery/non-bloody diarrhea,
abdominal cramps, and nausea. In addition, myalgia, mal-
aise, and headache are commonly reported.  Low-grade
fever may be present.  Dehydration is the most common
complication and may require intravenous replacement
fluids.
Diagnosis of norovirus infection is often made clinically in
individual cases, especially when other reasons for gas-
troenteritis can been ruled out.  Laboratory testing for
norovirus, using an RT-PCR assay to detect viral RNA in
the stool, is available at some reference laboratories and
in most state public health laboratories, including the cas-
Laboratory Testing of Shiga-Toxin
Producing Esherichia coli
Jennifer Meredith, Ph.D.
DHEC, Bureau of Laboratories
Enterohemorrhagic Esherichia coli (EHEC) is recognized
as an important cause of diarrhea, hemorrhagic colitis
(bloody diarrhea), and hemolytic uremic syndrome
(HUS).  Perhaps the most notable EHEC is E.coli
O157:H7, which was recently associated with an
outbreak of contaminated spinach that
resulted in 199 confirmed cases and
three deaths in 26 states.  However,
more than 100 non-O157:H7
serotypes are also capable of causing
similar serious il lnesses. The
pathogenicity of these organisms is
associated with the production of
shiga-like toxins, and they are
therefore known collectively as Shiga-
toxin producing E. coli (STEC). Cattle
and small ruminants are natural
reservoirs of STEC, and domestic
animals have been demonstrated to
be asymptomatic carriers (1).  It is
estimated that STEC causes 110,000
human illnesses a year in the United
States, and greater than or equal to
30 percent are caused by non-O157
serogroups of E. coli.
Two shiga-toxins are produced by
STEC: Stx1 and Stx2.  A single strain
can produce one or both of these
toxins.  Stx1 and Stx2 share DNA
sequence similarity with the shiga-
toxin produced by Shigella
dysenteriae, and their mechanism of
action is similar to that of Ricin toxin –
they inactivate the 60S ribosomal
subunit, blocking protein synthesis.
Local action of the cytotoxins Stx1 and/
or Stx2 results in hemorrhagic colitis.
One or both of the shiga-toxins may
also enter the blood and bind to the Gb3 receptor
found on kidney endothelial cells.  This can lead to a
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cade of events that culminates in DHEC Bureau of Labo-
ratories.  Testing should be considered in the event of
outbreaks of gastroenteritis in healthcare and other insti-
tutional facilities as well as certain other settings.  When
laboratory testing is indicated, the virus can best be iden-
tified from stool specimens taken within 48 to 72 hours
after the onset of symptoms, although results can be ob-
tained as long as seven days after the onset of symptom.
Special attention to hand hygiene practices is very
important in reducing transmission. Patients with
suspected norovirus infection should be managed with
Standard Precautions.  However, Contact Precautions
should be used when caring for diapered or incontinent
persons, during outbreaks in a facility, and when there is
the possibility of splashes that might lead to contamination
of clothing. Persons cleaning areas heavily contaminated
with vomitus or feces should wear surgical masks.  In an
outbreak setting, placing patients with suspected norovirus
infection in private rooms or clustering potentially infected
patients should be considered.
The Centers for Disease Control (CDC) recommend either
chlorine bleach or U.S. Environmental Protection Agency
(EPA) approved disinfectants for use in controlling
transmission of norovirus infection. Chlorine bleach
should be applied to hard, non-porous, environmental
surfaces at a dilution of 1 part household bleach solution
to 50 parts water. In areas with high levels of soiling and
resistant surfaces, a higher concentration of bleach is
recommended.  When norovirus contamination is
suspected, cleaning procedures that increase the
aerosolization of norovirus should not be utilized, such as
vacuuming carpets or buffing hard surface floors.
Contaminated carpeting should be disinfected with a
chemical disinfectant if possible, and then steam cleaned
for a minimum 5-minute contact time at a minimum
temperature of 170 degrees Fahrenheit.  Environmental
disinfection recommendations in the literature include the
need to disinfect all heavy hand contact surfaces such as
food preparation surfaces, self-service utensil handles,
faucets, tables, chairs, counters, door handles, push
plates, railings, elevator buttons, telephones, keyboards,
vending machine keyboards, pens, pencils, casino chips,
cards, slot machines, sports equipment, etc. Public
restroom surfaces, including faucet handles, soap
dispensers, stall doors and latches, toilet seats and
handles, and towel dispensers are also important heavy
fecal contamination areas that require disinfection.
In South Carolina there has been a recent increase in the
number of Norovirus outbreaks reported to DHEC. This
increase is consistent with the national trend of increased
Norovirus reports.  In 2006 a total of 28 outbreaks of
laboratory confirmed Norovirus were reported to DHEC.
Between January 1, 2007 and March 15, 2007, a total of 29
outbreaks of laboratory confirmed Norovirus were reported
to DHEC, representing this recent increase. DHEC
requests that facilities contact the regional DHEC public
health office if there is an increase in gastroenteritis among
persons in the facility.
References:
FDA, CFSAN Risk Profile Norovirus (Draft)
Centers for Disease Control and Prevention -
http://www.cdc.gov/
American Academy of Pediatrics, The Red Book – 2006 Report
of the Committee on Infectious Diseases, 27th edition.
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obstruction of the renal vasculature and renal failure.
Production of shiga-toxin alone isn’t enough to produce
disease.  Other important virulence factors are intimin
(eae), which facilitates an intimate attachment to intestinal
enterocytes, and hemolysin (e-hyl). Antibiotic treatment
may increase the chances of developing HUS – although
there is conflicting evidence.
Traditionally, laboratory confirmation of E.coli  O157:H7
relied on its inability to ferment sorbitol.  This has made
the organism relatively easy to distinguish from other
strains of  E. coli, including non-O157 isolates. Because
sorbitol fermentation is only 50-80 percent sensitive for
the detection of O157:H7 and because it is not possible to
biochemically differentiate STEC producers from their less
virulent counterparts, the only way we can currently screen
for STEC is by shiga-toxin detection.   This can be done by
two methods:  enzyme immunoassay (EIA) and
polymerase chain reaction (PCR).  The STEC EIA detects
shiga-toxins 1 and 2 in stool, but does not distinguish
which toxin is present or what organism is producing the
toxin. Citrobacter and Enterobacter species and Shigella
dysenteriae can also cause HUS and produce shiga-toxins
that cross react in the EIA. Large commercial laboratories
(notably Lab Corp and Quest) are no longer culturing stool
specimens for STEC.  Instead, they offer only the shiga
toxin EIA test to their clients.  The STEC EIA can be very
sensitive (79–100 percent) and specific (96 – 98 percent):
however, physicians must use care in interpreting these
tests for their patients.  A positive STEC EIA does not confirm
a diagnosis of E. coli O157:H7.
Commercial laboratories do not perform follow up cultures
to identify the shiga toxin producing bacteria in the toxin
positive samples, but because O157:H7 is a reportable
disease, enrichment broths are sent to the Bureau of
Laboratories (BOL) for isolation of STEC for epidemiologic
purposes.  Timing of this referral is critical – many are no
longer viable when they reach the state lab.  Specimens
that are non-viable are forwarded to the CDC, where a
PCR is performed for four virulence factors: stx1, stx2, eae,
and e-hyl.  Presence of DNA confirms the diagnosis of
STEC.  While the EIA is sensitive and specific (100 percent
and 98 percent respectively), culture must be performed
for serotyping and epidemiological studies.  Pulsed-field
gel electrophoresis (PFGE) is performed on all STEC
isolates to identify potential clusters of food borne illness.
All cases of diarrhea investigated by DHEC with no
apparent cause (negative for Norovirus or other enteric
organisms) are screened for shiga-toxin production.
Some laboratories use bloody diarrhea as a criteria for
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Preventing Illnesses and Injuries
Associated with Animal Contact Settings
Marcia Headrick, DVM, MPH
State Public Health Veterinarian
DHEC, Division of Acute Disease Epidemiology
Venues where humans and animals commonly interact
include public stables, petting zoos, traveling photo
opportunities, schools, children’s parties, livestock shows,
and animal rides.  These activities normally increase in
the summer because of the general increase in outdoor
activities and family vacations/outings.  Although there is
always some risk involved when interacting with animals,
awareness of the hazards and careful behavior will
decrease the chances of turning a routine activity into a
disaster.
Although enteric bacterial i l lnesses are the most
commonly reported health risks associated with animals
in public settings, multiple other health risks are of
concern. For example, allergies can be associated with
animal dander, scales, fur, feathers, urine, and saliva.
Additional health concerns include injuries, rabies
exposures, and other infections. Both wild and domestic
animals are unpredictable and can cause serious injuries,
particularly to small children.  Also, animals infected with
enteric pathogens (e.g., E. coli O157:H7, Salmonella, and
Campylobacter) frequently exhibit no signs of illness and
may shed pathogens intermittently.
Injuries
Injuries associated with animals in public settings include
bites, kicks, falls, scratches, stings, crushing of the hands
or feet, and being pinned between the animal and a fixed
object. These injuries have been associated with multiple
species, including big cats (e.g., tigers), monkeys,
domestic animals, and zoo animals.
Infections
Multiple bacterial, viral, fungal, and parasitic agents have
been associated with animal contact. These organisms
are transmitted through various modes.  Exposure to
animal feces can result in infection with E. coli O157:H7,
Salmonella, and Campylobacter.   Infections from animal
bites are common and frequently require extensive
treatment or hospitalization. Bacterial pathogens that are
frequently associated with animal bites include
Pasteurella, Staphylococcus, Streptococcus,
Capnocytophaga canimorsus, Bartonella henselae (cat
scratch disease), and Streptobacillus moniliformis (rat
bite fever). Certain monkey species (especially macaques)
that are kept as pets or used in public exhibitions can be
infected with herpes B virus, either asymptomatically or
with mild oral lesions. Human exposure through bites or
fluids can result in a fatal meningoencephalitis. Because
of difficulties with laboratory testing to confirm monkey
infection and high herpes B prevalence, monkey bites can
require intensive public health and medical follow-up.
testing for E. coli O157:H7, however this can be a poor
indicator.  One study found that 52 percent of cases of
STEC would have been missed if only bloody diarrhea
were tested (2). Stx2 is strongly associated with diarrhea
and eae with HUS (3)
Nationally the most common non-O157 serogroups are:
O26 (22 percent), O111 (16 percent), O103 (12 percent),
O121 (8 percent), O45 (7 percent), and O145 (5 percent).
These 6 serotypes accounted for 71 percent of the isolates
recovered from 1983 to 2002 (3).  In the last year, South
Carolina has seen four serotypes of E.coli:  O157:H7,
O55:H7, O118:H16, and O121:H19.  Strain O157:H7
remains most common, but this may be because many
laboratories screen for it specifically and are not capable
of detecting non-O157 isolates.  The BOL has been actively
pursuing non-O157 isolates since July 2006 and maintains
reagents to serogroup O111 and O26.  As additional
serogroups are identified in the state, capacity will be
increased to detect those that are most common.
A recent case of non-O157 STEC in a Lexington County
18-month-old demonstrated the challenge of daycare
exclusion for patients with STEC illness.  The child had
diarrhea and cramps, but never developed bloody stool or
HUS.  A STEC EIA performed at a reference laboratory was
positive, however broth submitted to the BOL did not grow
in culture.  The child submitted a second stool sample two
weeks after the initial EIA. This sample was also positive
by EIA and grew a non-O157, non-O111, non-O26 E. coli.
Serological testing by the CDC identified the organism as
E. coli O55:H7, and PCR detected two virulence factors:
stx2 and eae.  At the suggestion of the physician, the child
was excluded from daycare until two consecutive negative
cultures were obtained (27 days). The organism may be
shed in the stool for several weeks.  A study of day-care
associated infections in Germany showed that patients
with diarrhea or hemorrhagic colitis shed for a median
duration of 13 days (range of 2-62 days) and patients with
HUS shed for a median duration of 21 days (range of 5-
124 days) (4). Other studies reported a median duration of
29 days (5). Duration appears to vary inversely with age,
with younger children shedding longer, and studies
disagree on whether severity of illness affects duration of
shedding (6, 4, 7). Free fecal shiga-toxin may remain
measurable for four to six weeks; therefore, isolation of
the organism is critical to avoid unnecessary exclusion
from daycare.  It is unknown how many patients actually
follow this rule and return to the doctor for follow-up testing.
However the amount of testing required to confirm two
negative cultures in an 18-month-old over a four week
period (eight stool specimens) suggests that few patients
or their parents are as conscientious.
References:
1. Busch et al. EID. 13:348. 2007
2. Gavin et al. Clin Micro Newsletter 26:7. 2004
3. Brooks et al. JID. 2005:192
4. Karch et al., J. Clin Micro. 33:1602
5. Shah et al. Clin Infect Dis. 1996. 23:835-86
6. Belongia, et al. JAMA. 1993. 269:883-88
7. Oai et al. J Infect Dis. 1988. 157:1054-57
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Skin contact with animals in public settings might also
result in human infection. Ringworm infection caused by
Trichophyton species and Microsporum gypseum have
been documented among pet and livestock owners.
Ringworm infection in 23 persons and multiple animal
species were traced to a Microsporum canis infection in a
hand-reared zoo tiger cub. Orf virus infections (contagious
ecthyma or sore mouth) have occurred in goats and sheep
at a children’s petting zoo and in a lamb used for an Easter
photo opportunity.  In 2003, multiple cases of monkeypox
occurred among persons who had had contact with
infected prairie dogs either at a child care center or a pet
store.
Ecto- and endoparasites pose concerns when humans
and exhibit animals interact. Sarcoptes scabiei is a skin
mite that infests humans and animals, including swine,
dogs, cats, foxes, cattle, and coyotes. Although human
infestation from animal sources is usually self-limiting,
skin irritation and itching may occur for multiple days and
be difficult to diagnose. Animal fleas bite humans, which
increases the risk for infection or allergic reaction. In
addition, fleas are the intermediate host for a tapeworm
species that can infect children. Multiple other animal
helminths might infect humans through fecal-oral contact
or through contact with animals or contaminated earth.
Tuberculosis (TB) is another disease of concern in certain
animal settings. Twelve circus elephant handlers at an
exotic animal farm were infected with Mycobacterium
tuberculosis, and one handler had signs consistent with
active disease after three elephants died of TB. Medical
history and testing of the handlers indicated that the
elephants had been a probable source of exposure for the
majority of the human infections. At a zoo, seven animal
handlers who were previously negative for TB tested
positive after a Mycobacterium bovis outbreak in
rhinoceroses and monkeys.
Zoonotic pathogens may also be transmitted by direct or
indirect contact with reproductive fluids, aborted fetuses,
or newborns from infected dams. Live-birthing exhibits,
usually involving livestock (e.g., cattle, pigs, goats, or
sheep), are popular at agricultural fairs. Although the public
usually does not have direct contact with animals during
birthing, newborns and their dams are frequently available
for petting and observation afterward. Q fever (Coxiella
burnetii), leptospirosis, listeriosis, brucellosis, and
chlamydiosis are serious zoonoses that can be associated
with contact with reproductive materials.  C. burnetii is a
rickettsial organism that most frequently infects cattle,
sheep, and goats. The disease can cause abortion in
animals, but more frequently the infection is asymptomatic.
During parturition, infected animals shed substantial
numbers of organisms that might become aerosolized.
The majority of persons exposed to C. burnetii develop an
asymptomatic infection, but clinical illness can range from
an acute influenza-like il lness to l ife-threatening
endocarditis. A Q fever outbreak involving 95 confirmed
case-patients and 41 hospitalizations was linked to goats
and sheep giving birth at petting zoos. These petting zoos
were in indoor shopping malls, indicating that indoor-
birthing exhibits might pose an increased risk for Q fever
transmission.
Chlamydophila psittaci infections cause respiratory
disease (commonly called psittacosis) and are usually
acquired from psittacine birds. For example, an outbreak
of C. psittaci pneumonia occurred among the staff at a
Zoo.
Rabies Exposures
Contact with mammals may expose persons to rabies
through contamination of mucous membranes, bites,
scratches, or other wounds with infected saliva or nervous
tissue. Although no human rabies deaths caused by
animal contact in public exhibits have been recorded,
multiple rabies exposures have occurred, requiring
extensive public health investigation and medical follow
up. Persons have received rabies postexposure
prophylaxis (PEP) after being exposed to rabid or
potentially rabid animal species (including cats, goats,
bears, sheep, ponies, and dogs) at sites including pet
stores, county fairs, petting zoos, schools, and rodeo
events. Prompt assessment and treatment are critical for
this disease, which is usually fatal.
Brucellosis
Marcia Headrick, DVM, MPH
State Public Health Veterinarian
DHEC, Division of Acute Disease Epidemiology
Human cases of brucellosis are listed as an “urgently
reportable condition” on the SC Department of Health and
Environmental Control (DHEC) List of Reportable
Conditions.  Suspect or probable cases should be reported
to DHEC within 24 hours by phone.   Brucellosis is caused
by a bacterial pathogen and is often associated with
exposure to infected animals or animal products.  It is
also included on the list of potential bioterrorism agents.
In addition to transmission via infected animals and animal
products, Brucella sp . may be transmitted via
aerosolization in animal kennels or microbiological
laboratories.  Contact with aborted animal fetal tissues or
fluids are an important source of infection for veterinarians,
animal producers, and breeders. Ingestion of
unpasteurized milk and cheeses made from unpasteurized
milk are also risk factors associated with brucella infection.
There have been two confirmed cases of human
brucellosis reported to DHEC thus far in 2007.  One case
was imported (the patient was exposed while traveling
abroad.  The other case was acquired locally and
associated with contact to infected feral swine carcasses
during processing.
Although human brucellosis is not common in the US
(about 100-200 cases are diagnosed per year according
to the Centers for Disease Control and Prevention (CDC),
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HPV Disease in the United States and
South Carolina and the HPV Vaccine
Shirley Jankelevich, MD
Medical Epidemiologist
DHEC, Division of Acute Disease Epidemiology
Human papilloma viruses (HPV) are a large family of more
than 100 types of small DNA viruses that exhibit a high
degree of tissue and cellular specificity.  Some HPV types
infect nongenital skin and cause benign lesions, verrucae,
and plantar warts.  Other types infect genital skin and
mucous membranes.  These HPV types are divided into
low and high risk, based on their capacity to induce cancer.
Of the 15 high-risk HPV types, HPV types 16 and 18 are
responsible for approximately 70 percent of squamous
cell cancers of the cervix. HPV 16 and 18 can also cause
low-grade cervical dysplasia and benign genital warts.
Low risk HPV types 6 and 11 cause approximately 90
percent of benign genital warts and have low oncogenic
potential.
Genital HPV infection is one of the most common sexually
transmitted infections in females and males, with the
majority being asymptomatic, unrecognized, or subclinical.
Although most young persons can clear HPV infections
with no clinical consequences, certain infections persist
and result in warts, precancerous changes, and invasive
cancers of the anogenital region in both males and
females.  In 2000, approximately 6.2 million new HPV
infections occurred among females and males aged 15–
44 years in the United States with 75 percent (4.6 million)
of these new infections occurring among 15–24 year old
females and males.  The most common clinical
manifestation of HPV infection is genital warts.  In the
United States, an estimated 1.4 million people have genital
warts, and 500,000 to 1 million new cases occur each
year.
The development of cervical cancer is preceded by
persistent HPV infection.  Infection with HPV 16 or 18 may
progress to high-grade cervical dysplasia within three
years and to cancer within a 10-year period.  Cervical
cancer remains a major cause of morbidity and mortality
in women in the U.S.  In 2002, cervical cancer was the
tenth most common cancer in women and the second
most common cancer in women in their reproductive years.
An estimated 9,710 new cases of cervical cancer and 3,710
cervical cancer deaths occurred in the U.S. in 2006.
South Carolina has one of the highest incidence and
mortality rates due to cervical cancer in the United States.
The incidence of cervical cancer in 2002 was greater in
South Carolina  than the United States., and the S.C. age-
adjusted mortality rate was the sixth highest in the U.S. for
the 2000-2003 period.  Racial disparities continue to play
a role in the high rates of cervical cancer incidence in South
Carolina, with black and Hispanic women having
significantly higher rates than white women.  Mortality due
to cervical cancer in South Carolina is also significantly
South Carolina has some unique sources of potential
exposure.  The SC Department of Natural Resources
(DNR) has conducted studies of feral swine in South
Carolina and found that brucellosis is enzootic (endemic)
in the wild hog population.  Hunting wild hogs is a popular
hunting activity in South Carolina since the wild hog
population is plentiful and destructive to native flora and
fauna.  The hunters of these wild hogs and the individuals
who process the carcasses for human consumption are
at risk of infection with B. suis, the Brucella species that
can be found in both wild and domestic swine (South
Carolina commercially raised swine are brucellosis-free).
The DNR periodically reminds hunters of this risk in  DNR
publications, but at-risk patients may fail to link an illness
to their hunting activities.  Therefore, it is important to query
patients with compatible illness regarding any wild hog
hunting or processing activities.
International travel is also a risk factor for exposure to
Brucella sp., particularly in the Mediterranean basin.
Another term for brucellosis is Malta Fever, named after
the island of Malta in the middle of the Mediterranean Sea.
Goats are an important source of infection in the
Mediterranean region.  B. melitensis is the species
associated with goats.  Many rural communities rely on
goat meat and milk as a source of food and income.  Soft
cheeses produced from unpasteurized goat milk can be
purchased by tourists unaware of the risk.  Brucella sp.
are also found in cattle, sheep, deer, elk, dogs, coyotes,
and other animals worldwide.  Human to human spread
is rare, but possible, through sexual transmission or
breast-feeding of infants. The incubation period for
brucellosis in humans ranges from less than a week to
several months.
Brucellosis in humans is characterized by vague
symptoms often associated with the “flu.”  Signs and
symptoms include fever, night sweats, headaches, back
pain, fatigue, and arthralgias.  Severe illness can affect
the central nervous system and heart.  Signs and symptoms
may diminish and recur resulting in an undulating pattern.
(Hence the name Undulant Fever was historically ascribed
to brucellosis.)
Most commercial laboratories can conduct testing for
Brucella sp.  In general, the screening tests are fairly
sensitive but not extremely specific, so false positives may
occur.  Confirmatory testing is recommended as well as
testing of both acute and convalescent sera collected at
least two weeks apart.  Samples may be sent to the  DHEC
Bureau of Laboratories for confirmatory testing.
Treatment of brucellosis with rifampin and doxycycline for
six weeks has been successful in humans.  Other
treatment regimens are also published.
The CDC case definition for human brucellosis is located
on the CDC Web site at:
http://www.cdc.gov/epo/dphsi/casedef
brucellosis_current.htm
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higher for black women than white women. The excess
mortality in black women is related to the diagnosis at
later stages of cervical cancer.
The cost of treatment of HPV genital warts as well as
screening, follow-up, and treatment of HPV precancerous
disease and HPV-induced malignancies makes HPV
infection the second most costly sexually transmitted
infection after HIV.  The annual total direct cost for the
treatment of anogenital warts for all age groups in the
United States is estimated at $167.4 million.  The annual
direct HPV-attributable costs for follow-up of abnormal Pap
test results and for treatment of related neoplasia is
estimated at $3.4 billion to $3.6 billion among women of
all ages.  In addition, the estimated annual cost of treating
the expected 12,800 cases of invasive cervical cancer that
occur each year is $146.4 million.
Two prophylactic HPV vaccines have been developed.  The
first one is a quadrivalent vaccine that prevents infection
with two low-risk HPV types, 6 and 11, and two high-risk
types, 16 and 18.  This vaccine has received FDA approval.
The second is a bivalent vaccine that has been shown in
clinical trials to prevent infection with the two high-risk HPV
types, 16 and 18.  At the time of this writing, FDA approval
is pending for this vaccine.  Both vaccines are expected to
prevent 70 percent of cervical cancers.  In addition, the
quadrivalent vaccine will also prevent infection with HPV 6
and 11, which cause 90 percent of genital warts.  Both
HPV vaccines are subunit virus-like particle (VLP) vaccines
that do not contain live virus vaccines and thus cannot
produce HPV disease.
The Advisory Committee for Immunization Practices (ACIP)
and the Centers for Disease Control (CDC) recommend
that HPV immunization be administered at the 11-12 year
old visit.  This recommendation appears in the “2007
Recommended Immunization Schedules for Persons 0-
18 Years”.  However, at the physician’s discretion, it can
be administered to girls as young as 9 years of age.  One
of the reasons for choosing the 11-12 year old visit is that
HPV vaccine efficacy is based on preventing infection with
HPV.  Therefore, it is important to administer the vaccine
before sexual activity begins. According to 2005 data from
the Youth Risk Behavior Surveillance System conducted
by CDC, of the female high school students interviewed,
3.7 percent had sexual intercourse before age 13, 62.4
percent had sexual intercourse by grade 12, and 14.3
percent had sexual intercourse with at least four persons
by grade 12.  In addition, 37.2 percent of sexually active
male and female high school students had not used a
condom at last sexual intercourse.
Some important points to remember about prophylactic
HPV vaccines are the following: 1) vaccination will not pre-
vent infection with the HPV types not contained in the vac-
cine; 2) vaccination will not cause regression of HPV in-
fection caused by HPV types in the vaccine if the infection
is already present at the time of vaccination; 3) individuals
with impaired immune defenses (e.g. use of immuno-
suppressive therapy, a genetic defect, human immunode-
ficiency virus [HIV] infection, or other causes) may have
reduced antibody response to active immunization and
decreased protection from the vaccines; and 4) adoles-
cent girls and women who have been or are sexually ac-
tive should continue to receive routine Pap testing because
the HPV vaccine does not provide protection against sev-
eral high-risk HPV types that cause 30 percent of cervical
cancers.
The series of three immunizations will cost $360, a sig-
nificant financial barrier.  While several private health in-
surance plans in South Carolina, including State Health
Plan and BlueChoice, will provide coverage for the HPV
vaccine, many economically disadvantaged adolescents
do not have such coverage.  The ACIP has approved a
resolution to add the quadrivalent HPV Vaccine to the Vac-
cine for Children Program (VFC).  This resolution is ex-
tremely important in providing HPV vaccine to many eco-
nomically disadvantaged adolescents.  However, VFC cov-
erage of vaccines is limited to children 18 and under who
are uninsured, underinsured or Medicaid eligible and to
children of Native American or Alaskan ancestry. To qualify,
the children must receive immunizations through a Feder-
ally Qualified Health Center (FQHC) or Rural Health Clinic
(RHC).  While South Carolina often has additional federal
and state funding for vaccines through the Vaccine Assur-
ance for All Children (VAFAC) program, which provides vac-
cines free of charge for children through the age of 18 who
are underinsured (i.e., insurance plan does not cover vac-
cine), these funds are not available at this time.  One alter-
native for provision of HPV vaccine for underinsured chil-
dren is referral of these children to FQHCs and Commu-
nity Health Centers (CHCs).   Another alternative is having
the patient bear the cost of the immunization.  Despite
these barriers, the VFC program that is administered
through South Carolina will provide funding for the HPV
vaccine for a significant number of adolescents.  Any health
care provider, including those involved in pediatrics, gyne-
cology, family medicine, or internal medicine who would
like to be able to administer HPV vaccine to VFC-eligible
adolescents may enroll in the S.C. program by contacting
the DHEC Immunization Division at (800) 277-4687.
Conclusions.  HPV infection in women and men is very
common.  HPV infections can lead to the development of
cervical neoplasia and cancer.  HPV disease is one of the
most common and costly sexually transmitted diseases.
The HPV vaccine is highly effective in preventing infection
with HPV and will prevent 70 percent of cases of cervical
cancer in the immunized population.  Vaccinating adoles-
cent girls before sexual debut will result in a greater im-
pact of the vaccine on the prevention of cervical cancer as
well as on decreasing the spread of HPV types contained
in the vaccine within the population of sexually active per-
sons.
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Year-to-Date Summary of Selected Reportable Conditions - January 1, 2007 - March 28, 2007
C o n d i t io n  C o n f ir m e d  P r o b a b le  T o t a l  
A n im a l B it e — P E P  R e c o m m e n d e d  7 4  0  7 4  
A s e p t ic  m e n in g it is  1 7  1  1 8  
B r u c e l lo s is  2  0  2  
C a m p y lo b a c te r io s is  4 6  1  4 7  
C ig u a te ra  f is h  p o is o n in g  0  0  0  
C ry p to s p o r id io s is  1 0  0  1 0  
C y c lo s p o r ia s is  0  0  0  
D e n g u e  F e v e r  0  1  1  
E h r lic h io s is -  h u m a n  g ra n u lo c y t ic  0  0  0  
E h r lic h io s is -  h u m a n  m o n o c y t ic  0  0  0  
E h r lic h io s is -  h u m a n -  o th e r& u n s p e c  0  0  0  
E n c e p h a lit is - W e s t  N ile  0  0  0  
E n te ro h e m . E . c o l i  O 1 5 7 :H 7  0  0  0  
E n te ro h e m .E .c o l i s h ig a to x + -  ? s e r o g rp  0  0  0  
E n te ro h e m .E .c o l i -  s h ig a to x+ -  n o n - O 1 5 7  0  0  0  
G ia rd ia s is  1 0  0  1 0  
G ro u p  A  S tre p to c o c c u s -  in v a s iv e  2 1  0  2 1  
G ro u p  B  S tre p to c o c c u s -  in v a s iv e  2  0  2  
H a e m o p h ilu s  in f lu e n z a e -  in v a s iv e  1 2  0  1 2  
H e m o ly tic  u re m ic  s y n d -  p o s td ia r rh e a l 1  0  1  
H e p a t it is  A -  a c u te  3  0  3  
H e p a t it is  B -  a c u te  2 0  1  2 1  
H e p a t it is  B  v iru s  in fe c t io n -  c h ro n ic  7 1  3 6  1 0 7  
H e p a t it is  C -  a c u te  0  0  0  
H e p a t it is  C  V ir u s  I n fe c t io n -  p a s t o r  p r e s e n t  6 3 8  2 8 8  9 2 6  
H e p a t it is  D e lta  c o -  o r  s u p e r- in fe c t io n -  a c u te  0  0  0  
H e p a t it is  E -  a c u te  0  0  0  
In f lu e n z a -  h u m a n  is o la te s  3 9  0  3 9  
K a w a s a k i d is e a s e  0  0  0  
L e g io n e l lo s is  3  1  4  
L is te r io s is  0  0  0  
L y m e  d is e a s e  2  0  2  
M a la r ia  0  0  0  
M u m p s  0  0  0  
N e is s e r ia  m e n in g it id is -  in v a s iv e  (M e n in g .  d is e a s e )  3  0  3  
P e r tu s s is  1 2  8  2 0  
R o c k y  M o u n ta in  s p o t te d  f e v e r  0  4  4  
S .  a u re u s -  c o a g + -  m e th -  o r  o x i-  re s is ta n t  ( M R S A ) 1  0  1  
S a lm o n e llo s is  1 2 6  2  1 2 8  
S h ig a  to x in -p ro d u c in g  E s c h e r ic h ia  c o l i (S T E C ) 0  0  0  
S h ig e l lo s is  9  0  9  
S t re p  p n e u m o n ia e -  in v a s iv e  9 6  0  9 6  
S t re p to c o c c a l d is e a s e -  in v a s iv e -  o th e r  5  0  5  
T e ta n u s  0  0  0  
T o x ic - s h o c k  s y n d r o m e -  s ta p h y lo c o c c a l 0  0  0  
V a r ic e lla  (C h ic k e n p o x )  2 4 3  1 5 2  3 9 5  
V ib r io  p a ra h a e m o ly t ic u s  1  0  1  
V ib r io  s p p .-  n o n - to x ig e n ic -  o th e r  o r  u n s p e c if ie d  1  0  1  
V ib r io  v u ln i fic u s  in fe c t io n  0  0  0  
W e s t  N i le  F e v e r  0  0  0  
Y e r s in io s is  2  0  2  
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